These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28393006)

  • 1. Small cell lung cancer transformation during immunotherapy with nivolumab: A case report.
    Imakita T; Fujita K; Kanai O; Terashima T; Mio T
    Respir Med Case Rep; 2017; 21():52-55. PubMed ID: 28393006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases.
    Liu H; Chen LH; Zhang ZH; Wang N; Zhuang SH; Chen H; Du J; Pang LJ; Qi Y
    Front Oncol; 2022; 12():1022705. PubMed ID: 36439460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases.
    Shen Q; Qu J; Sheng L; Gao Q; Zhou J
    Front Oncol; 2021; 11():619371. PubMed ID: 34094904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation of Lung Squamous Cell Carcinoma to Small Cell Lung Cancer After Immunotherapy Resistance: A Case Report.
    Wang D; Ye W; Chen D; Shi Q; Ma D
    Cancer Manag Res; 2023; 15():803-808. PubMed ID: 37583652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Tokaca N; Wotherspoon A; Nicholson AG; Fotiadis N; Thompson L; Popat S
    Lung Cancer; 2017 Sep; 111():65-68. PubMed ID: 28838401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
    J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation.
    Abdallah N; Nagasaka M; Abdulfatah E; Shi D; Wozniak AJ; Sukari A
    Lung Cancer (Auckl); 2018; 9():85-90. PubMed ID: 30498383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
    Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
    Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abscopal effect of radiation therapy and nivolumab in a patient with combined small-cell lung cancer: a case report.
    Wang W; Li L; Wu S; Shen J; Huang C; Chen Y; Li S
    Immunotherapy; 2022 Aug; 14(12):909-914. PubMed ID: 35787148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
    BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological Complete Response after Immune-Checkpoint Inhibitor Followed by Salvage Surgery for Clinical Stage IV Pulmonary Adenocarcinoma with Continuous Low Neutrophil-to-Lymphocyte Ratio: A Case Report.
    Higuchi M; Kawamata T; Oshibe I; Soeta N; Saito T; Hojo H; Matsumura Y; Suzuki H
    Case Rep Oncol; 2021; 14(2):1124-1133. PubMed ID: 34413743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report.
    Nishikawa K; Okuma Y; Hashimoto K; Kashima J
    Tohoku J Exp Med; 2019 Apr; 247(4):247-250. PubMed ID: 30996212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.
    Rittberg R; Banerji S; Green S; Qing G; Dawe DE
    Cureus; 2020 Oct; 12(10):e11224. PubMed ID: 33269152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined small cell lung carcinoma and giant cell carcinoma: a case report.
    Saito T; Tsuta K; Fukumoto KJ; Matsui H; Konobu T; Torii Y; Yokoi T; Kurata T; Kurokawa H; Uemura Y; Saito Y; Murakawa T
    Surg Case Rep; 2017 Dec; 3(1):52. PubMed ID: 28364180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.